2,4,6-triallyloxy-1,3,5-triazine

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: comparable to guideline study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1984

Materials and methods

Test guideline

Test guideline 1

Qualifier:

equivalent or similar to guideline

Guideline:

EU Method B.1 (Acute Toxicity (Oral))

Version / remarks:

Cited as Directive 84/449/EEC, B.1

Deviations:

yes

Remarks:

; purity not reported

Test guideline 2

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

Deviations:

yes

Remarks:

; purity not reported

GLP compliance:

no

Remarks:

test was performed prior to GLP-requirement

Test type:

standard acute method

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

2,4,6-triallyloxy-1,3,5-triazine

EC Number:

202-936-7

EC Name:

2,4,6-triallyloxy-1,3,5-triazine

Cas Number:

101-37-1

Molecular formula:

C12H15N3O3

IUPAC Name:

tris(prop-2-en-1-yloxy)-1,3,5-triazine

Test animals

Species:

rat

Strain:

Wistar

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Winkelmann, Borchen
- Age at study initiation: females 64-72 d; males 51-59 d
- Weight at study initiation: females 141-158 g; males 127-187 g
- Fasting period before study: 16 h; overnight
- Housing: individually Macrolon cage type II
- Diet: ssniff, ad libitum
- Water: ad libitum
- Acclimation period: 5 days


ENVIRONMENTAL CONDITIONS: according to guideline

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

peanut oil

Details on oral exposure:

VEHICLE
- Concentration in vehicle: 112; 164; 241; 353 and 518 g/ L
- Amount of vehicle (if gavage): 2.15 mL/ kg

Doses:

male: 353, 518, 760, 1116 mg/ kg bw
female: 240, 518, 1116 mg/ kg bw

No. of animals per sex per dose:

5

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: no data
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs

Statistics:

Probit analysis

Results and discussion

Effect levels

Effect levels 1

Key result

Sex:

female

Dose descriptor:

LD50

Effect level:

760 mg/kg bw

Based on:

test mat.

95% CL:

345 - 1 671

Effect levels 2

Key result

Sex:

male

Dose descriptor:

LD50

Effect level:

927 mg/kg bw

Based on:

test mat.

95% CL:

587 - 1 464

Effect levels 3

Key result

Sex:

male/female

Dose descriptor:

LD50

Effect level:

753 mg/kg bw

Based on:

test mat.

95% CL:

578 - 1 070

Mortality:

Male
353 mg/ kg : 0/5
518 mg/ kg : 1/5 day 3 p.a.
760 mg/ kg : 2/5 day 2 and 3 p.a.
1116 mg/ kg : 4/5 day 2 and 3 p.a.

Female
240 mg/ kg : 0/5
518 mg/ kg : 2/5 day 2 and 3 p.a.
1116 mg/ kg : 4/5 day 2 and 3 p.a.

Clinical signs:

other: ataxia, decrease of muscle tone, loss of reflexes, strenuous respiration, lacrimation, decrease of salivation, piloerection

Gross pathology:

highest dose group: red coloured fluid in the stomach (all animals), brightening of liver (1 animal)

Other findings:

Signs of toxicity occurred as early as 5 min p.a. and were evident until 4 days p.a. in the surviving animals. Deaths occurred on day 2 or 3 p.a.

Applicant's summary and conclusion

Interpretation of results:

Category 4 based on GHS criteria

Conclusions:

The test substance caused death under the conditions tested. The LD50 is considered to be 753 mg/kg bw males/females as well as for females alone. Predominant clinical signs observed were ataxia, decrease of muscle tone, loss of reflexes, strenuous respiration, lacrimation, decrease of salivation, piloerection which were present 5 min p.a. and remaind by day 4 p.a.